INsIde thIs Issue - FDAnews · For more details, see New Studies on Page 2. New Results: ... NCT01928056 TORRENT DRUG 4. COMPLETED 1 MISS-ING 18 YEARS 45 YEARS HEALTHY NCT01928069

Highlights of Changes This Week at ClinicalTrials.gov:New Sponsors: Six sponsors registered studies at ClinicalTrials.gov for the first time this week. Those sponsors are Argentum Medical, Glycom, Kang Stem Holdings, Minneamrita Therapeutics, Seragon Pharmaceuticals and Vidara Therapeutics Research. For more details, see New Sponsors on Page 2.

New Studies: Sixty-nine new studies were registered this week, including studies sponsored by Amgen, AstraZeneca, Bayer, Boeh-ringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Novo Nordisk and Shire. For more details, see New Studies on Page 2.

New Results: Twenty-seven industry-sponsored studies posted results this week, including studies by AstraZeneca, Bausch & Lomb, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck and Pfizer. For more details, see New Results on Page 6.

New Study Status: One hundred and one studies are reporting changes in their status as planning, recruiting, ongoing or completed this week. Among the sponsors are Abbott, AbbVie, AstraZeneca, Bausch & Lomb, Bristol-Myers Squibb, Celgene, Cubist, Eli Lilly, Genentech, Gil-ead, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Mannkind, Med-Immune, Medtronic, Novo Nordisk, Otsuka, Pfizer, Sanofi, Takeda, Teva and Vertex. For more details, see New Study Status on Page 7.

Vol. 2, No. 35Aug. 29, 2013

New Sponsors ..........Page 2

New Studies .............Page 2

New Results .............Page 6

New Study Status .....Page 7

Studies Opening a First Site in a New Country ...Page 12

Studies Opening Additional Sites in a Country ..Page 21

Study Sites by Country ..................Page 39

Studies Under Planning .................Page 40

Studies Ended or Halted .....................Page 41

INsIde thIs Issue

SummAry of lATeST TriAl updATeS

Week ending Aug. 29 Aug. 22 Aug. 15 Aug. 8 Total

New Sponsors 6 12 8 12 38New Studies 69 107 62 105 343New Results 27 33 38 38 136New Study Status 101 96 92 100 389Studies Opening a First Site in a New Country 224 277 269 323 1,093Studies Opening Additional Sites in a Country 397 597 867 479 2,340Studies Under Planning 46 49 49 50 194Studies Ended or Halted 23 14 12 11 60

(See Highlights, Page 2)

CliniCal Trial Magnifier Weekly Aug. 29, 2013page 2

Studies Opening a First Site in a New Country: Two hundred and twenty-four new study sites launched this week in countries where the sponsors did not have study sites. For more details, see Studies Opening a First Site in a New Country on Page 12.

Studies Opening Additional Sites in a Country: Three hundred and ninety-seven new study sites launched this week in countries where the sponsors already had study sites. For more details, see Studies Opening Additional Sites in a Country on Page 21.

Study Sites by Country: A handy table that lists all countries with first-time and additional study sites that launched this week can be found at Study Sites by Country on Page 39.

Studies Under Planning: About 10% of the studies listed as in the planning stage are replaced each week. This week’s 46 listings include planned studies at AstraZeneca, Bristol-Myers Squibb, Celgene, Glaxo- SmithKline, Janssen, Medtronic, Merck, Novartis, Pfizer, and Zimmer. For more details, see Studies Under Planning on Page 40.

Studies Ended or Halted: Twenty-three studies were terminated, suspended or withdrawn this week, including studies sponsored by Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Novartis and Teva. For more details, see Studies Ended or Halted on Page 41.

ideNTifier1 SpoNSor Type2 STATuS pHASe3 SiZe (N)

miN AGe

mAX AGe CoNdiTioN

NCT01927705 KANG STEM GENETIC 1. PLANNING 1 3020

YEARS60

YEARSATOPIC DERMATITIS

NCT01927900 GLYCOMDIETARY SUP.

1. PLANNING NA 10018

YEARS60

YEARSGASTROINTESTINAL SYMPTOMS

NCT01823835 SERAGON DRUG 2. RECRUITING 1 7218

YEARSN/A BREAST CANCER

NCT01927211 ARGENTUM DEVICE 2. RECRUITING NA 66018

YEARSN/A POST-OPERATIVE PAIN

NCT01927965 MINNEAMRITA DRUG 3. ONGOING 1 5418

YEARSN/A

GASTROINTESTINAL TUMORS

NCT01929382 VIDARA DRUG 3. ONGOING 1 4018

YEARS55

YEARSHEALTHY

Highlights, from Page 1

NeW SpoNSorS

This table lists new sponsors that have never previously registered studies at ClinicalTrials.gov.

1 Identifier: The official study ID given by ClinicalTrials.gov. 2 When the type field is empty, it is commonly a noninterventional study. 3 “NA” in the Phase field indicates that the sponsor has not provided any trial phase information; “NA” commonly represents a noninterventional study, but it can also represent an interventional device trial.

NeW STudieS

This table lists every new study registered in the past week.


miN AGe

mAX AGe CoNdiTioN

NCT01926509 MERCK DRUG 1. PLANNING 1 1818

YEARS70

YEARSPULMONARY HYPERTENSION

NCT01927224 BAYER DRUG 1. PLANNING 1 3618

YEARS45

YEARSCHAGAS DISEASE

(See New Studies, Page 3)(Return to Page 1)

http://www.clinicaltrials.gov/ct2/show/NCT01927705








CliniCal Trial Magnifier WeeklyAug. 29, 2013 page 3


miN AGe

mAX AGe CoNdiTioN

NCT01927341 NOVARTIS DRUG 1. PLANNING 1 9018

YEARSN/A

METASTATIC COLORECTAL CANCER

NCT01927705 KANG STEM GENETIC 1. PLANNING 1 3020

YEARS60


NCT01928394 BMS BIOLOGICAL 1. PLANNING 1 16018

YEARSN/A SOLID TUMORS

NCT01928459 NOVARTIS DRUG 1. PLANNING 1 5518

YEARSN/A

METASTATIC SOLID TUMORS

NCT01928472 NOVARTIS BIOLOGICAL 1. PLANNING 1 40018

YEARS64

YEARSH7N9 INFLUENZA

NCT01928563 DONG-A DRUG 1. PLANNING 1 2420

YEARS45

YEARSHEALTHY

NCT01928862 FERRING DRUG 1. PLANNING 1 759

YEARS16

YEARSBOWEL PREPARATION

NCT01929109 ELI LILLY DRUG 1. PLANNING 1 6018

YEARS85

YEARS

RENAL INSUFFICIENCY, CHRONIC

NCT01929330 GSK DRUG 1. PLANNING 1 3618

YEARS65

YEARSALOPECIA

NCT01926847 BAYER DRUG 1. PLANNING 2 2018

YEARS70

YEARSRAYNAUD DISEASE

NCT01927198 ARDEA DRUG 1. PLANNING 2 16018

YEARS70

YEARSGOUT

NCT01927419 BMS BIOLOGICAL 1. PLANNING 2 15018

YEARSN/A MELANOMA

NCT01927913 SHIRE DRUG 1. PLANNING 2 5018

YEARSN/A

METABOLIC DISEASES

NCT01928381 ASTRAZENECA DRUG 1. PLANNING 2 6518

YEARS75

YEARSDIABETIC NEUROPATHY

NCT01928615HOFFMANN-LA ROCHE

DRUG 1. PLANNING 2 5018


NCT01928901 BIONORICA DRUG 1. PLANNING 2 5625

YEARS40

YEARSCURRENT SMOKERS

NCT01926782 REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A

HYPERCHOLESTER-OLEMIA




NCT01927055 CHELSEA DRUG 1. PLANNING 3 45018

YEARSN/A

DOPAMINE DEFICIENCY

NCT01928771 ASTRAZENECA BIOLOGICAL 1. PLANNING 3 1,13418

YEARS75

YEARSASTHMA

NCT01929044BOEHRINGER INGELHEIM


YEARS70

YEARSINTESTINAL DISEASES

NCT01929317 GSK DRUG 1. PLANNING 3 8020

YEARSN/A

PARKINSON DISEASE

(See New Studies, Page 4)


(Return to Page 1)

New Studies, from Page 2

























miN AGe

mAX AGe CoNdiTioN

NCT01926496 LEO DRUG 1. PLANNING 4 48018

YEARSN/A ACTINIC KERATOSIS

NCT01926951 KONA DEVICE 1. PLANNING NA 2018

YEARSN/A HYPERTENSION

NCT01927575 FUJIFILM DEVICE 1. PLANNING NA 3018

YEARSN/A HIP INJURY

NCT01927900 GLYCOMDIETARY SUP.


YEARS60

YEARSGASTROINTESTINAL SYMPTOMS

NCT01928875GE HEALTHCARE

DEVICE 1. PLANNING NA 50018

YEARS80

YEARSSURGICAL INTERVENTION

NCT01928979 BAYER OTHER 1. PLANNING NA 15018

YEARSN/A ATRIAL FIBRILLATION

NCT01929291 GSK BIOLOGICAL 1. PLANNING NA 60011

YEARS64

YEARSADVERSE EVENTS BOOSTRIX

NCT01926587 ONCONOVA DRUG 2. RECRUITING 1 4018

YEARSN/A

CHRONIC MYELOMONOCYTIC LEUKEMIA

NCT01928147 PRESIDIO DRUG 2. RECRUITING 1 14418

YEARS65

YEARSHEPATITIS C, CHRONIC

NCT01928368 AMGEN DRUG 2. RECRUITING 1 9618

YEARS45

YEARSASTHMA

NCT01929213 DONG-A DRUG 2. RECRUITING 1 3020

YEARS45

YEARSHEALTHY

NCT01929226 ELUSYS BIOLOGICAL 2. RECRUITING 1 28018

YEARSN/A

INHALATIONAL ANTHRAX

NCT01926444 GICARE DRUG 2. RECRUITING 2 24040

YEARS70

YEARSCOLONIC DISEASES

NCT01928433 MERLION DRUG 2. RECRUITING 2 25818

YEARSN/A

ACUTE PYELONEPHRITIS

NCT01928940 GSK DRUG 2. RECRUITING 2 1220

YEARSN/A SOLID TUMOURS

NCT01929096JIANGSU SIMCERE

DRUG 2. RECRUITING 2 40035

YEARS75

YEARSACUTE ISCHEMIC STROKE

NCT01927263 NICHI-IKO BIOLOGICAL 2. RECRUITING 3 23020

YEARS75

YEARSRHEUMATOID ARTHRITIS

NCT01927861 NOVO NORDISK DRUG 2. RECRUITING 3 483

YEARS11

YEARSNOONAN SYNDROME

NCT01928537 ONCONOVA DRUG 2. RECRUITING 3 9018

YEARSN/A CYTOPENIA



YEARS55

YEARSTOOTH DISEASES

NCT01926912 JANSSEN DRUG 2. RECRUITING 4 45018

YEARSN/A SCHIZOPHRENIA

NCT01927757 AMGEN BIOLOGICAL 2. RECRUITING 4 25018

YEARSN/A

RHEUMATOID ARTHRITIS


2. RECRUITING NA 24018

YEARS65

YEARSHEALTHY


(See New Studies, Page 5)


(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN

NCT01927068 COVIDIEN DEVICE 2. RECRUITING NA 50018

YEARSN/A

PERIPHERAL ARTERIAL DISEASE

NCT01927211 ARGENTUM DEVICE 2. RECRUITING NA 66018

YEARSN/A

POST-OPERATIVE PAIN

NCT01927679 INNOVADERM DRUG 2. RECRUITING NA 1018

YEARSN/A

PIGMENTATION FROM VISIBLE LIGHT

NCT01928953 ASTRAZENECA 2. RECRUITING NA 90018

YEARS85

YEARS

OPIOID INDUCED CONSTIPATION

NCT01929369 VOLCANO 2. RECRUITING NA 10018

YEARS85

YEARSTHROMBOSED AV GRAFTS

NCT01927965 MINNEAMRITA DRUG 3. ONGOING 1 5418

YEARSN/A

GASTROINTESTINAL TUMORS

NCT01929382 VIDARA DRUG 3. ONGOING 1 4018

YEARS55

YEARSHEALTHY

NCT01929200 ZHEJIANG DRUG 3. ONGOING 2 12018

YEARS75

YEARSNON-SMALL-CELL LUNG CANCER

NCT01926548 CORPORATION DRUG 4. COMPLETED 1 2820

YEARS55

YEARSHEALTHY

NCT01926652 SHIN POONG DRUG 4. COMPLETED 1 3420

YEARS55

YEARSHEALTHY

NCT01928056 TORRENT DRUG 4. COMPLETED 1MISS-ING

18 YEARS

45 YEARS

HEALTHY

NCT01928069 TORRENT DRUG 4. COMPLETED 1MISS-ING

18 YEARS

45 YEARS

HEALTHY

NCT01928316 XIAN-JANSSEN DRUG 4. COMPLETED 1 2418

YEARS40

YEARSHEALTHY

NCT01928914 GSK DRUG 4. COMPLETED 1 26018

YEARS65

YEARSMALARIA, VIVAX

NCT01929070 HANMI DRUG 4. COMPLETED 1 1220

YEARS55

YEARSHEALTHY


YEARS65

YEARSACNE VULGARIS

NCT01230060BAUSCH & LOMB

DEVICE 4. COMPLETED 3 12218

YEARSN/A CATARACT

NCT01928628 LG LIFE DRUG 4. COMPLETED 3 44920

YEARS75

YEARSHYPERTENSION

NCT01928888 BAYER DRUG 4. COMPLETED 4 47718

YEARS65

YEARSHEARTBURN

NCT01928992 FUJIFILM DEVICE 4. COMPLETED NA 10018


NCT00014131CALIFORNIA STEM CELL

BIOLOGICAL 7. TERMINATED 1 916

YEARSN/A KIDNEY CANCER


BIOLOGICAL 7. TERMINATED 2 8018

YEARSN/A BRAIN TUMORS



(Return to Page 1)
























NeW reSulTS

This table lists all industry-sponsored studies with results posted during the past week.


miN AGe

mAX AGe CoNdiTioN

NCT00595088 BIOCANCELL BIOLOGICAL 3. ONGOING 2 4718

YEARSN/A

SUPERFICIAL BLADDER CANCER

NCT00398086 CELGENE DRUG 4. COMPLETED 1 6718

YEARSN/A

PANCREATIC CANCER

NCT00565136AMERICAN MEDICAL


YEARSN/A

FECAL INCONTINENCE


DRUG 4. COMPLETED 1 3618

YEARS45

YEARSHEALTHY

NCT01653158 PFIZER DRUG 4. COMPLETED 1 4618

YEARSN/A

NON-HEMATOLOGIC MALIGNANCIES

NCT00615017 ASTRAZENECA DRUG 4. COMPLETED 2 7018

YEARSN/A SEVERE SEPSIS

NCT00642642 FIBROCELL BIOLOGICAL 4. COMPLETED 2 12218

YEARS65

YEARSACNE SCARRING


YEARS65

YEARSHEPATITIS C


YEARSN/A SEPTIC SHOCK

NCT00113607JOHNSON & JOHNSON


YEARSN/A OVARIAN CANCER


YEARSN/A TYPE 2 DIABETES

NCT00673231 ASTRAZENECA DRUG 4. COMPLETED 3 1,24018

YEARS80

YEARSTYPE 2 DIABETES

NCT00753922 MENTOR DEVICE 4. COMPLETED 3 1,00818

YEARSN/A BREAST REVISION


YEARSN/A

INADEQUATE GLYCAEMIC CONTROL


YEARSN/A

INADEQUATE GLYCAEMIC CONTROL


YEARSN/A ASTHMA



YEARSN/A CATARACT


YEARSN/A HIGH BLOOD SUGAR


YEARS14

YEARSDENTAL CARIES

NCT00766831 JANSSEN DRUG 4. COMPLETED 4 19020

YEARSN/A CANCER PAIN

NCT00814658 JANSSEN DRUG 4. COMPLETED 4 2265

YEARSN/A DEMENTIA


YEARS75

YEARSANGINA PECTORIS

(See New results, Page 7)


(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN



YEARSN/A

MYELOGENOUS LEUKEMIA, ACUTE

NCT01657942 INSIGHTEC DEVICE 2. RECRUITING 1 4055

YEARS75

YEARSPROSTATE CANCER

NCT01754844 ASTRAZENECA DRUG 2. RECRUITING 1 7218

YEARS55

YEARSCOPD

NCT01496742 GENENTECH DRUG 2. RECRUITING 2 26018

YEARSN/A

NON-SMALL CELL LUNG CANCER

NCT01685281 ALCOBRA DRUG 2. RECRUITING 2 3618

YEARS55

YEARSADHD

NCT01448057 NOVARTIS DRUG 2. RECRUITING 3 24418

YEARS65

YEARSSNEEZING


DRUG 2. RECRUITING 3 170 N/A11

YEARSCATARACT

NCT01544491 NOVARTIS DRUG 2. RECRUITING 3 106 N/A18

YEARSRENAL TRANSPLANT

NCT01663623 GSK BIOLOGICAL 2. RECRUITING 3 40018

YEARSN/A VASCULITIS


DRUG 2. RECRUITING 4 2,80018

YEARSN/A ANEMIA



YEARSN/A

HEPATITIS C, CHRONIC

NCT01424475 GSK GENETIC 2. RECRUITING NA 4018

YEARSN/A

PARKINSON DISEASE

NCT01110486 ABBVIE DRUG 3. ONGOING 1 12018


NCT01136733 EISAI DRUG 3. ONGOING 1 18018

YEARSN/A

METASTATIC RENAL CELL CARCINOMA


(See New Study Status, Page 8)


miN AGe

mAX AGe CoNdiTioN

NCT01843660 XIAN-JANSSEN DRUG 4. COMPLETED 4 1,05918

YEARS65

YEARSNECK PAIN

NCT01278485 MERCK DRUG 4. COMPLETED NA 72630

YEARSN/A

TYPE 2 DIABETES MELLITUS

NCT01422538 ULTHERA DEVICE 4. COMPLETED NA 3035

YEARS60

YEARSSKIN LAXITY

NCT00862082 PROACTAD DRUG 7. TERMINATED 1 1418

YEARSN/A

HEPATOCELLULAR CARCINOMA

NCT00929474 ST JUDE DEVICE 7. TERMINATED 4 1718

YEARSN/A HEART FAILURE

New results, from Page 6

NeW STudy STATuS

This table lists studies that reported updates in their status in the past week such as recruiting, ongoing or completed.

(Return to Page 1)






















miN AGe

mAX AGe CoNdiTioN

NCT01209130 GENENTECH DRUG 3. ONGOING 1 9218

YEARSN/A

CHRONIC LYMPHOCYTIC LEUKEMIA

NCT01446159 MEDIMMUNE DRUG 3. ONGOING 1 18718


NCT01457417 DEKKUN DRUG 3. ONGOING 1 3930

YEARSN/A


NCT01598129ONCOS THERAPEUTICS

GENETIC 3. ONGOING 1 1218

YEARSN/A SOLID TUMOUR


DRUG 3. ONGOING 1 4818

YEARSN/A

LYMPHOMA, B-CELL

NCT00769470TRANSLATIONAL ONCOLOGY

BIOLOGICAL 3. ONGOING 2 14018

YEARS70

YEARSBREAST CANCER

NCT00936715 GILEAD DRUG 3. ONGOING 2 2418

YEARS75

YEARSCHRONIC HEPATITIS B

NCT01217632 FIBROGEN DRUG 3. ONGOING 2 22818

YEARS75

YEARSLIVER FIBROSIS


YEARS69

YEARSHEPATITIS B


YEARSN/A

LYMPHOMA, B-CELL


YEARSN/A

RENAL CELL CARCINOMA

NCT01576718 TEVA DRUG 3. ONGOING 2 62212

YEARSN/A ASTHMA

NCT01701232 BIOCAD BIOLOGICAL 3. ONGOING 2 9218

YEARS95

YEARSSPLENIC LYMPHOMA

NCT01754935 VERTEX DRUG 3. ONGOING 2 4018

YEARS65


NCT01183780 ELI LILLY BIOLOGICAL 3. ONGOING 3 1,05018

YEARSN/A

COLORECTAL CANCER

NCT01345929 CUBIST DRUG 3. ONGOING 3 50018

YEARSN/A PYELONEPHRITIS

NCT01373580REVISION OPTICS

DEVICE 3. ONGOING 3 37335

YEARS65

YEARSPRESBYOPIA

NCT01445665 CUBIST DRUG 3. ONGOING 3 50018

YEARSN/A

INTRA-ABDOMI-NAL INFECTION

NCT01468233 ABBVIE BIOLOGICAL 3. ONGOING 3 30018

YEARSN/A

HIDRADENITIS SUPPURATIVA

NCT01471574 BMS DRUG 3. ONGOING 3 30018

YEARS70

YEARSHEPATITIS C, GENOTYPE 1


YEARS75

YEARS



YEARS75

YEARS


New Study Status, from Page 7


(See New Study Status, Page 9)(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN


YEARSN/A


NCT01580228 MERCK DRUG 3. ONGOING 3 46618

YEARSN/A




YEARSN/A SURGERY

NCT01626222 NOVARTIS DRUG 3. ONGOING 3 30218

YEARSN/A

METASTATIC BREAST CANCER

NCT01674634 AUXILIUM BIOLOGICAL 3. ONGOING 3 60018

YEARSN/A

DUPUYTREN’S CONTRACTURE

NCT01674712 ABBOTT DRUG 3. ONGOING 3 57718

YEARS80

YEARSDYSLIPIDEMIA



YEARSN/A

DIABETES MELLITUS, TYPE 2

NCT00658827 JANSSEN OTHER 3. ONGOING 4 370 N/A N/AINFLAMMATORY BOWEL DISEASE

NCT01231659 NOVARTIS DRUG 3. ONGOING 4 7318


NCT01503476 GIVEN IMAGING DEVICE 3. ONGOING 4 17018

YEARSN/A

GASTRO ESOPHAGEAL REFLUX DISEASE

NCT01477671 SANOFI 3. ONGOING NA 2,614 5 YEARS10

YEARS

DENGUE HEMORRHAGIC FEVER


3. ONGOING NA 21018

YEARSN/A


NCT00565136AMERICAN MEDICAL


YEARSN/A

FECAL INCONTINENCE

NCT00697346 MILLENNIUM DRUG 4. COMPLETED 1 5818

YEARSN/A NK LYMPHOMA

NCT01097590 IBD DEVICE 4. COMPLETED 1 2318

YEARS75

YEARSULCERATIVE COLITIS

NCT01166490SEATTLE GENETICS


YEARSN/A

PANCREATIC NEOPLASMS

NCT01205737 TEVA BIOLOGICAL 4. COMPLETED 1 18618

YEARS80

YEARSDLBCL

NCT01291004 TEVA DRUG 4. COMPLETED 1 20618

YEARS35

YEARSORAL CONTRACEPTIVE

NCT01317797 TAKEDA DRUG 4. COMPLETED 1 2418

YEARSN/A


NCT01385566 MERCK BIOLOGICAL 4. COMPLETED 1 22350

YEARSN/A HERPES ZOSTER

NCT01454349 SOPHIRIS DRUG 4. COMPLETED 1 4050

YEARS80

YEARSPROSTATIC HYPERPLASIA

NCT01521455 HANMI DRUG 4. COMPLETED 1 5620

YEARS75

YEARSASTHMA




(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN


YEARS80

YEARSHEALTHY

NCT01748552 ELI LILLY DRUG 4. COMPLETED 1 3621

YEARS65

YEARSDIABETES MELLITUS, TYPE 2

NCT00137969 GENENTECH DRUG 4. COMPLETED 2 25716

YEARS75

YEARSLUPUS ERYTHEMATOSUS

NCT00402168 BMS DRUG 4. COMPLETED 2 17118

YEARSN/A

RENAL TRANSPLANT

NCT00508404 AMGEN DRUG 4. COMPLETED 2 15418

YEARSN/A

METASTATIC COLORECTAL CANCER

NCT00948090 OTSUKA DRUG 4. COMPLETED 2 20718

YEARS65

YEARSLYMPHOMA

NCT01109264JIANGSU SIMCERE


YEARS75

YEARS


NCT01146535 AMARILLO DRUG 4. COMPLETED 2 4020

YEARS65

YEARSINFLUENZA A VIRUS INFECTION

NCT01296711 UCB BIOLOGICAL 4. COMPLETED 2 19018

YEARSN/A


NCT01310114 CELGENE BIOLOGICAL 4. COMPLETED 2 4418

YEARS80

YEARS

POSTERIOR CEREBRAL ARTERY STROKE

NCT01348152 TSUMURA DRUG 4. COMPLETED 2 5018

YEARS80

YEARSFUNCTIONAL CONSTIPATION

NCT01356160 GILEAD DRUG 4. COMPLETED 2 35118

YEARS70


NCT01491529 NOVARTIS DRUG 4. COMPLETED 2 15430

YEARS80

YEARSANTI-DYSKINESIA AGENTS

NCT01555151 NOVARTIS DRUG 4. COMPLETED 2 61612

YEARSN/A ASTHMA

NCT01684800 FERRING DRUG 4. COMPLETED 2 17820

YEARSN/A NOCTURIA

NCT01694498 FERRING DRUG 4. COMPLETED 2 18320

YEARSN/A NOCTURIA

NCT00299104 GENENTECH DRUG 4. COMPLETED 3 75518

YEARS80




NCT00753922 MENTOR DEVICE 4. COMPLETED 3 1,00818

YEARSN/A

BREAST REVISION

NCT00911326 NAVIDEA DRUG 4. COMPLETED 3 20018

YEARSN/A

HEAD/NECK CARCINOMA

NCT01202760 ELI LILLY DRUG 4. COMPLETED 3 1,00218

YEARSN/A


NCT01249664 BAYER BIOLOGICAL 4. COMPLETED 3 12218

YEARSN/A

MYOPIA, PATHOLOGICAL




(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN

NCT01254019 GSK DRUG 4. COMPLETED 3 186 5 YEARS N/AMUSCULAR DYSTROPHIES


YEARSN/A BRONCHIECTASIS


YEARSN/A BRONCHIECTASIS

NCT01370642 MERCK DRUG 4. COMPLETED 3 29420

YEARS70


NCT01445951 MANNKIND DRUG 4. COMPLETED 3 51818

YEARSN/A


NCT01451398 MANNKIND DRUG 4. COMPLETED 3 35318


NCT01459367 TAKEDA DRUG 4. COMPLETED 3 60720

YEARSN/A

EROSIVE ESOPHAGITIS

NCT01470053 HANLIM DRUG 4. COMPLETED 3 34712

YEARSN/A

PERENNIAL ALLERGIC RHINITIS


YEARSN/A

DIABETIC PERIPHERAL NEUROPATHY

NCT01620489 NOVO NORDISK DRUG 4. COMPLETED 3 27918

YEARS80

YEARS


NCT01636401 DAEWOONG DRUG 4. COMPLETED 3 MISS-

ING 40

YEARSN/A COPD

NCT01680341 NOVO NORDISK DRUG 4. COMPLETED 3 27218

YEARSN/A


NCT01697956 TEVA DRUG 4. COMPLETED 3 99 6 YEARS11

YEARSALLERGIC RHINITIS


YEARSN/A ANALGESIA

NCT01308619 GALDERMA DRUG 4. COMPLETED 4 17018

YEARS70

YEARSROSACEA

NCT01322633 PFIZER OTHER 4. COMPLETED 4 61,86418

YEARSN/A ESOPHAGITIS


YEARS45

YEARS

HEALTHY LACTATING WOMEN

NCT00730548 MEDTRONIC BEHAVIORAL 4. COMPLETED NA 18018

YEARSN/A

CARDIAC DESYNCHRONIZA-TION


DRUG 4. COMPLETED NA 1,157 N/A N/A HYPERTENSION

NCT01395862 GSK DRUG 4. COMPLETED NA 1,001 N/A N/ARESPIRATORY DISORDERS

NCT01715155 ASTRAZENECA 4. COMPLETED NA 17118

YEARSN/A

METASTATIC BREAST CANCER



(Return to Page 1)























ideNTifier1 CouNTry SpoNSor Type2 STATuS pHASe3 SiZe (N)

miN AGe

mAX AGe CoNdiTioN

NCT01927224 ARGENTINA BAYER DRUG 1. PLANNING 1 3618

YEARS45

YEARSCHAGAS DIS-EASE

NCT01544491 ARGENTINA NOVARTIS DRUG 2. RECRUITING 3 106 N/A18

YEARSRENAL TRANS-PLANT

NCT01712516 ARGENTINA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01768572 ARGENTINA SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01875003 ARGENTINAHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01846611 AUSTRALIA JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A

FALLOPIAN TUBE NEOPLASMS

NCT01843387 AUSTRALIA MESO BIOLOGICAL 2. RECRUITING 1 3060

YEARS85

YEARSTYPE 2 DIABETES

NCT01785602 AUSTRALIA NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65

YEARSATOPIC DERMA-TITIS

NCT01835535 AUSTRALIA CARDIOSONIC DEVICE 2. RECRUITING 2 8018

YEARS80

YEARSHYPERTENSION

NCT01764997 AUSTRALIA SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01928615 AUSTRIAHOFFMANN-LA ROCHE



NCT01711619 AUSTRIA MEDTRONIC DEVICE 2. RECRUITING 4 20018

YEARSN/A

FAILED BACK SURGERY

NCT01838616 AUSTRIA GRENENTHAL DRUG 2. RECRUITING 4 24018

YEARSN/A

NEUROPATHIC PAIN

NCT01928901 BELGIUM BIONORICA DRUG 1. PLANNING 2 5625

YEARS40

YEARSCURRENT SMOK-ERS

NCT01785602 BELGIUM NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65


NCT01544491 BELGIUM NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01785875 BELGIUM AMGEN DRUG 2. RECRUITING 3 1,00018

YEARSN/A

HYPERPARATHY-ROIDISM

NCT01831765 BELGIUMNOVO NOR-DISK


YEARSN/A

DIABETES MEL-LITUS, TYPE 1

NCT01926912 BELGIUM JANSSEN DRUG 2. RECRUITING 4 45018


NCT01715909 BRAZILHOFFMANN-LA ROCHE


YEARSINFLUENZA

NCT01544491 BRAZIL NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01782326 BRAZIL NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01875003 BRAZILHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01926782 BULGARIA REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A

HYPERCHOLES-TEROLEMIA

STudieS opeNiNG A firST SiTe iN A NeW CouNTry

This table lists studies that launched a site in a country for the first time in the past week.


(See Studies opening a first Site in a New Country, Page 13)(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01928979 BULGARIA BAYER OTHER 1. PLANNING NA 15018

YEARSN/A

ATRIAL FIBRILLA-TION

NCT01785602 BULGARIA NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65


NCT01819129 CANADANOVO NORDISK


YEARSN/A


NCT01926782 CANADA REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01296555 CANADA GENENTECH DRUG 2. RECRUITING 1 21918

YEARSN/A SOLID CANCERS

NCT01822613 CANADA NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A

ESOPHAGEAL CARCINOMA

NCT01926444 CANADA GICARE DRUG 2. RECRUITING 2 24040

YEARS70

YEARSCOLONIC DIS-EASES

NCT01868061 CANADAHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA



YEARS17

YEARSASTHMA

NCT01927757 CANADA AMGEN BIOLOGICAL 2. RECRUITING 4 25018

YEARSN/A


NCT01927679 CANADA INNOVADERM DRUG 2. RECRUITING NA 1018

YEARSN/A

PIGMENTATION FROM VISIBLE LIGHT

NCT01928953 CANADA ASTRAZENECA 2. RECRUITING NA 90018

YEARS85

YEARSOPIOID INDUCED CONSTIPATION

NCT01929044 CHINABOEHRINGER INGELHEIM


YEARS70

YEARSINTESTINAL DIS-EASES

NCT01929096 CHINAJIANGSU SIMCERE


YEARS75

YEARSACUTE ISCHEMIC STROKE

NCT01836471 COLOMBIA NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01663402 COLOMBIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A

ACUTE CORO-NARY SYN-DROME

NCT01875003 COLOMBIAHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01926951 CZECH REP KONA DEVICE 1. PLANNING NA 2018


NCT01764997 CZECH REP SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01785875 CZECH REP AMGEN DRUG 2. RECRUITING 3 1,00018

YEARSN/A


NCT01875003 CZECH REPHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01902134 CZECH REP MENARINI DRUG 2. RECRUITING 3 60018

YEARS80

YEARSACUTE PAIN

NCT01927900 DENMARK GLYCOMDIETARY SUP.


YEARS60

YEARSGASTROINTESTI-NAL SYMPTOMS


(See Studies opening a first Site in a New Country, Page 14)

Studies opening a first Site in a New Country, from Page 12

(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN

NCT01798706 DENMARK SANOFI DRUG 2. RECRUITING 3 34070


NCT01926912 DENMARK JANSSEN DRUG 2. RECRUITING 4 45018


NCT01928875 FINLANDGE HEALTHCARE


YEARS80


NCT01926496 FRANCE LEO DRUG 1. PLANNING 4 48018

YEARSN/A

ACTINIC KERATOSIS

NCT01928979 FRANCE BAYER OTHER 1. PLANNING NA 15018

YEARSN/A

ATRIAL FIBRILLATION

NCT01794520 FRANCE ABBVIE DRUG 2. RECRUITING 1 3018

YEARSN/A

MULTIPLE MYELOMA

NCT01822613 FRANCE NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01544491 FRANCE NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01875003 FRANCEHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01929109 GERMANY ELI LILLY DRUG 1. PLANNING 1 6018

YEARS85

YEARSRENAL INSUFFICIENCY

NCT01926847 GERMANY BAYER DRUG 1. PLANNING 2 2018

YEARS70

YEARSRAYNAUD DISEASE

NCT01926496 GERMANY LEO DRUG 1. PLANNING 4 48018

YEARSN/A

ACTINIC KERATOSIS

NCT01928875 GERMANYGE HEALTHCARE


YEARS80


NCT01928979 GERMANY BAYER OTHER 1. PLANNING NA 15018

YEARSN/A

ATRIAL FIBRILLATION

NCT01336634 GERMANY GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01377480 GERMANY MERCK DRUG 2. RECRUITING 2 16018

YEARS50

YEARSCHAGAS DISEASE

NCT01696045 GERMANY BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA

NCT01785602 GERMANY NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65


NCT01836471 GERMANY NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01928433 GERMANY MERLION DRUG 2. RECRUITING 2 25818

YEARSN/A

ACUTE PYELONEPHRITIS

NCT01831765 GERMANYNOVO NORDISK


YEARSN/A


NCT01875003 GERMANYHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01711619 GERMANY MEDTRONIC DEVICE 2. RECRUITING 4 20018

YEARSN/A

FAILED BACK SURGERY

NCT01926912 GERMANY JANSSEN DRUG 2. RECRUITING 4 45018





(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN



YEARS65

YEARSHEALTHY VOLUNTEER

NCT01926912 GREECE JANSSEN DRUG 2. RECRUITING 4 45018


NCT01822613 HONG KONG NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01782326 HONG KONG NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01926782 HUNGARY REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01928875 HUNGARYGE HEALTHCARE


YEARS80


NCT01544491 HUNGARY NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01768702 HUNGARY CARDIO3 BIOLOGICAL 2. RECRUITING 3 24018

YEARS80

YEARSHEART FAILURE

NCT01875003 HUNGARYHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01836471 INDIA NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01445678 INDIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01926782 ISRAEL REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01445678 ISRAEL CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01764997 ISRAEL SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01768702 ISRAEL CARDIO3 BIOLOGICAL 2. RECRUITING 3 24018

YEARS80

YEARSHEART FAILURE

NCT01776424 ISRAEL BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A

PREVENTION & CONTROL

NCT01875003 ISRAELHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01711619 ISRAEL MEDTRONIC DEVICE 2. RECRUITING 4 20018

YEARSN/A

FAILED BACK SURGERY

NCT01926912 ISRAEL JANSSEN DRUG 2. RECRUITING 4 45018


NCT01336634 ITALY GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01544491 ITALY NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01875003 ITALYHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01854047 JAPAN SANOFI DRUG 2. RECRUITING 2 60018

YEARSN/A ASTHMA

NCT01928940 JAPAN GSK DRUG 2. RECRUITING 2 1220

YEARSN/A SOLID TUMOURS

NCT01261325 JAPAN UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY




(Return to Page 1)




























miN AGe

mAX AGe CoNdiTioN

NCT01782326 JAPAN NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01927263 JAPAN NICHI-IKO BIOLOGICAL 2. RECRUITING 3 23020

YEARS75


NCT01927861 JAPANNOVO NORDISK


YEARS11

YEARSNOONAN SYNDROME

NCT01928563 KOREA, SOUTH DONG-A DRUG 1. PLANNING 1 2420

YEARS45

YEARSHEALTHY MALE SUBJECTS

NCT01822613 KOREA, SOUTH NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01929213 KOREA, SOUTH DONG-A DRUG 2. RECRUITING 1 3020

YEARS45

YEARSHEALTHY VOLUNTEERS


YEARSN/A ASTHMA

NCT01761266 KOREA, SOUTH EISAI DRUG 2. RECRUITING 3 94018

YEARSN/A

HEPATOCELLU-LAR CARCINOMA

NCT01492504 KOREA, SOUTH BMS DRUG 2. RECRUITING NA 99018

YEARSN/A HEPATITIS C

NCT01445678 LATVIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01696266 LEBANONNOVO NORDISK

OTHER 2. RECRUITING NA 6,30018

YEARSN/A


NCT01830985 LITHUANIA VERTEX DRUG 2. RECRUITING 2 4018

YEARS65


NCT01261325 LITHUANIA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01904149 LITHUANIA MENARINI DRUG 2. RECRUITING 3 60018

YEARS75

YEARSACUTE PAIN

NCT01846273 MALAYSIA NOVARTIS DRUG 2. RECRUITING 4 32018

YEARSN/A

MACULAR DEGENERATION

NCT01696266 MALAYSIANOVO NORDISK


YEARSN/A


NCT01872689 MEXICOHOFFMANN-LA ROCHE


YEARSN/A

PULMONARY FIBROSIS

NCT01600092 MEXICO MERCK BIOLOGICAL 2. RECRUITING 3 9246

WEEKS12

WEEKSROTAVIRUS GAS-TROENTERITIS

NCT01712516 MEXICO NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01875003 MEXICOHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01903824 NETHERLANDS TEVA DRUG 1. PLANNING 1 4018

YEARS50

YEARSCOGNITIVE IMPAIRMENT

NCT01928875 NETHERLANDSGE HEALTHCARE


YEARS80


NCT01362244 NETHERLANDS GSK DRUG 2. RECRUITING 2 11018

YEARS70

YEARSPOLYPS, NASAL

NCT01785602 NETHERLANDS NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65





(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01846611 NEW ZEALAND JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A


NCT01926951 NEW ZEALAND KONA DEVICE 1. PLANNING NA 2018


NCT01854047 NEW ZEALAND SANOFI DRUG 2. RECRUITING 2 60018

YEARSN/A ASTHMA

NCT01764997 NEW ZEALAND SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01927068 NEW ZEALAND COVIDIEN DEVICE 2. RECRUITING NA 50018

YEARSN/A

PERIPHERAL ARTERIAL DISEASE

NCT01926782 NORWAY REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01544491 NORWAY NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01798706 NORWAY SANOFI DRUG 2. RECRUITING 3 34070


NCT01875003 PERUHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01727141 PHILIPPINES NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01782326 PHILIPPINES NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01926782 POLAND REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01928979 POLAND BAYER OTHER 1. PLANNING NA 15018

YEARSN/A

ATRIAL FIBRILLATION

NCT01836471 POLAND NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01544491 POLAND NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01610414 POLAND GSK BIOLOGICAL 2. RECRUITING 3 1,47418


NCT01831765 POLANDNOVO NORDISK


YEARSN/A


NCT01875003 POLANDHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA



YEARS65


NCT01785602 ROMANIA NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65


NCT01836471 ROMANIA NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01819129 RUSSIANOVO NORDISK


YEARSN/A


NCT01846611 RUSSIA JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A





(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN

NCT01928979 RUSSIA BAYER OTHER 1. PLANNING NA 15018

YEARSN/A

ATRIAL FIBRILLATION

NCT01782326 RUSSIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01875003 RUSSIAHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01410890 RUSSIA GENZYME BIOLOGICAL 2. RECRUITING 4 208

YEARS18

YEARSACID MALTASE DEFICIENCY

NCT01926912 RUSSIA JANSSEN DRUG 2. RECRUITING 4 45018


NCT01696266 RUSSIANOVO NORDISK


YEARSN/A




YEARS65


NCT01445678 SERBIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01822613 SINGAPORE NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01761266 SINGAPORE EISAI DRUG 2. RECRUITING 3 94018

YEARSN/A


NCT01819129 SLOVAKIANOVO NORDISK


YEARSN/A


NCT01926782 SLOVAKIA REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01875003 SLOVAKIAHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01926782 SOUTH AFRICA REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01785602 SOUTH AFRICA NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65


NCT01830985 SOUTH AFRICA VERTEX DRUG 2. RECRUITING 2 4018

YEARS65


NCT01836471 SOUTH AFRICA NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01875003 SOUTH AFRICAHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01927341 SPAIN NOVARTIS DRUG 1. PLANNING 1 9018

YEARSN/A

COLORECTAL CANCER

NCT01786668 SPAIN PFIZER DRUG 2. RECRUITING 2 20018

YEARSN/A

ANKYLOSING SPONDYLITIS

NCT01764997 SPAIN SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01838616 SPAIN GRENENTHAL DRUG 2. RECRUITING 4 24018

YEARSN/A

NEUROPATHIC PAIN

NCT01926912 SPAIN JANSSEN DRUG 2. RECRUITING 4 45018


NCT01544491 SWEDEN NOVARTIS DRUG 2. RECRUITING 3 106 N/A18





(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01785875 SWEDEN AMGEN DRUG 2. RECRUITING 3 1,00018

YEARSN/A


NCT00685750 SWEDEN GSK PROCEDURE 2. RECRUITING NA 16018

YEARSN/A

LUNG CANCER, NON-SMALL CELL

NCT01822613 TAIWAN NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01897038 TAIWANHOFFMANN-LA ROCHE


YEARSN/A LIVER CANCER

NCT01336634 TAIWAN GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01610414 TAIWAN GSK BIOLOGICAL 2. RECRUITING 3 1,47418


NCT01782326 TAIWAN NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01492504 TAIWAN BMS DRUG 2. RECRUITING NA 99018


NCT01386528 THAILANDNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01855997 THAILANDHOFFMANN-LA ROCHE

2. RECRUITING NA 1,20018

YEARSN/A

HEPATITIS B, CHRONIC

NCT01928979 TURKEY BAYER OTHER 1. PLANNING NA 15018

YEARSN/A

ATRIAL FIBRILLATION

NCT01571284 TURKEY SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01875003 UKRAINEHOFFMANN-LA ROCHE


YEARS17

YEARSASTHMA

NCT01410890 UKRAINE GENZYME BIOLOGICAL 2. RECRUITING 4 208

YEARS18


NCT01929109 UK ELI LILLY DRUG 1. PLANNING 1 6018

YEARS85

YEARSRENAL INSUFFICIENCY

NCT01926782 UK REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01926496 UK LEO DRUG 1. PLANNING 4 48018

YEARSN/A

ACTINIC KERATOSIS

NCT01715909 UKHOFFMANN-LA ROCHE


YEARSINFLUENZA

NCT01822613 UK NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01928147 UK PRESIDIO DRUG 2. RECRUITING 1 14418

YEARS65


NCT01436487 UK ATHERSYS BIOLOGICAL 2. RECRUITING 2 14018

YEARS83

YEARSISCHEMIC STROKE

NCT01480479 UK CELLDEX DRUG 2. RECRUITING 3 44018

YEARSN/A GLIOBLASTOMA

NCT01544491 UK NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01768572 UK SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A





(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01831765 UKNOVO NORDISK


YEARSN/A


NCT01927341 USA NOVARTIS DRUG 1. PLANNING 1 9018

YEARSN/A

COLORECTAL CANCER

NCT01928459 USA NOVARTIS DRUG 1. PLANNING 1 5518


NCT01928472 USA NOVARTIS BIOLOGICAL 1. PLANNING 1 40018

YEARS64

YEARSH7N9 INFLUENZA

NCT01927198 USA ARDEA DRUG 1. PLANNING 2 16018

YEARS70

YEARSGOUT

NCT01928381 USA ASTRAZENECA DRUG 1. PLANNING 2 6518

YEARS75

YEARSDIABETIC NEUROPATHY

NCT01819129 USANOVO NORDISK


YEARSN/A


NCT01926782 USA REGENERON DRUG 1. PLANNING 3 70018

YEARSN/A


NCT01927055 USA CHELSEA DRUG 1. PLANNING 3 45018

YEARSN/A

DOPAMINE DEFICIENCY

NCT01927575 USA FUJIFILM DEVICE 1. PLANNING NA 3018

YEARSN/A HIP INJURY

NCT01657942 USA INSIGHTEC DEVICE 2. RECRUITING 1 4055

YEARS75

YEARSPROSTATE CANCER

NCT01926587 USA ONCONOVA DRUG 2. RECRUITING 1 4018

YEARSN/A

CHRONIC MY-ELOMONOCYTIC LEUKEMIA

NCT01928368 USA AMGEN DRUG 2. RECRUITING 1 9618

YEARS45

YEARSASTHMA

NCT01929226 USA ELUSYS BIOLOGICAL 2. RECRUITING 1 28018

YEARSN/A

INHALATIONAL ANTHRAX

NCT01836471 USA NOVARTIS DRUG 2. RECRUITING 2 33618

YEARSN/A ASTHMA

NCT01853878 USA GSK BIOLOGICAL 2. RECRUITING 2 22018

YEARSN/A


NCT01917383 USA INOTEK DRUG 2. RECRUITING 2 11018

YEARSN/A GLAUCOMA

NCT01926444 USA GICARE DRUG 2. RECRUITING 2 24040

YEARS70

YEARSCOLONIC DISEASES

NCT01761266 USA EISAI DRUG 2. RECRUITING 3 94018

YEARSN/A


NCT01769170 USA CHIMERIX DRUG 2. RECRUITING 3 45018

YEARS89

YEARSBK VIRUS (BKV)

NCT01785875 USA AMGEN DRUG 2. RECRUITING 3 1,00018

YEARSN/A




YEARSN/A





(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN

NCT01862640 USA OTSUKA DRUG 2. RECRUITING 3 56055

YEARS90

YEARS

NERVOUS SYSTEM DISEASES

NCT01928537 USA ONCONOVA DRUG 2. RECRUITING 3 9018

YEARSN/A CYTOPENIA

NCT01929031 USABOEHRINGER INGELHEIM


YEARS55

YEARSTOOTH DISEASES

NCT01927757 USA AMGEN BIOLOGICAL 2. RECRUITING 4 25018

YEARSN/A


NCT01883063 USA SONOMA DEVICE 2. RECRUITING NA 12065

YEARSN/A

DISTAL RADIUS FRACTURE

NCT01923285 USASPINAL MODULATION

DEVICE 2. RECRUITING NA 15222

YEARS75

YEARSCHRONIC LOWER LIMB PAIN

NCT01926873 USAHOFFMANN-LA ROCHE


YEARS65


NCT01927211 USA ARGENTUM DEVICE 2. RECRUITING NA 66018

YEARSN/A

POST-OPERATIVE PAIN

NCT01928953 USA ASTRAZENECA 2. RECRUITING NA 90018

YEARS85

YEARSOPIOID INDUCED CONSTIPATION

NCT01929369 USA VOLCANO 2. RECRUITING NA 10018

YEARS85

YEARSTHROMBOSED AV GRAFTS

NCT01727141 VIETNAM NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD



(See Studies opening Additional Sites in a Country, Page 22)

STudieS opeNiNG AddiTioNAl SiTeS iN A CouNTry

This table lists studies that launched additional sites in a country in the past week.


miN AGe

mAX AGe CoNdiTioN

NCT01377480 ARGENTINA MERCK DRUG 2. RECRUITING 2 16018

YEARS50

YEARSCHAGAS DISEASE

NCT01445678 ARGENTINA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A

INTRA- ABDOMINAL INFECTION

NCT01663402 ARGENTINA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A

ACUTE CORONARY SYNDROME

NCT01492504 ARGENTINA BMS DRUG 2. RECRUITING NA 99018


NCT01696266 ARGENTINANOVO NORDISK


YEARSN/A


NCT01696045 AUSTRALIA BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA


YEARSN/A ASTHMA

NCT01480479 AUSTRALIA CELLDEX DRUG 2. RECRUITING 3 44018


(Return to Page 1)






















miN AGe

mAX AGe CoNdiTioN

NCT01610414 AUSTRALIA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 AUSTRALIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A



YEARSN/A

TYPE 2 DIABETES

NCT01868061 AUSTRALIAHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01492504 AUSTRALIA BMS DRUG 2. RECRUITING NA 99018


NCT01785602 AUSTRIA NOVARTIS DRUG 2. RECRUITING 2 9218

YEARS65


NCT01261325 AUSTRIA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 AUSTRIANOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01480479 AUSTRIA CELLDEX DRUG 2. RECRUITING 3 44018


NCT01663402 AUSTRIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 AUSTRIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01696266 AUSTRIANOVO NORDISK


YEARSN/A



YEARSN/A


NCT01362244 BELGIUM GSK DRUG 2. RECRUITING 2 11018

YEARS70

YEARSPOLYPS, NASAL

NCT01696045 BELGIUM BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA


YEARSN/A ASTHMA

NCT01261325 BELGIUM UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01571284 BELGIUM SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01610414 BELGIUM GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 BELGIUM SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01768572 BELGIUM SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01768702 BELGIUM CARDIO3 BIOLOGICAL 2. RECRUITING 3 24018

YEARS80

YEARSHEART FAILURE

NCT01782326 BELGIUM NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD



Studies opening Additional Sites in a Country, from Page 21

(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN

NCT01868061 BELGIUMHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01711619 BELGIUM MEDTRONIC DEVICE 2. RECRUITING 4 20018

YEARSN/A

FAILED BACK SURGERY

NCT01855997 BELGIUMHOFFMANN-LA ROCHE


YEARSN/A


NCT01261325 BRAZIL UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01480479 BRAZIL CELLDEX DRUG 2. RECRUITING 3 44018


NCT01571284 BRAZIL SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01663402 BRAZIL SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01386528 BULGARIANOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01445678 BULGARIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01663402 BULGARIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 BULGARIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01868061 BULGARIAHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01696266 BULGARIANOVO NORDISK


YEARSN/A


NCT01855997 BULGARIAHOFFMANN-LA ROCHE


YEARSN/A




YEARSINFLUENZA



YEARSN/A

PULMONARY FIBROSIS

NCT01261325 CANADA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01480479 CANADA CELLDEX DRUG 2. RECRUITING 3 44018


NCT01571284 CANADA SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01600092 CANADA MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS

ROTAVIRUS GASTROEN-TERITIS

NCT01610414 CANADA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 CANADA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A

ACUTECORONARY SYNDROME




(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN

NCT01727141 CANADA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01776424 CANADA BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A

CARDIOVASCU-LAR EVENTS

NCT01782326 CANADA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01798706 CANADA SANOFI DRUG 2. RECRUITING 3 34070

YEARSN/A

TYPE 2 DIABETES

NCT01492504 CANADA BMS DRUG 2. RECRUITING NA 99018


NCT01696266 CANADANOVO NORDISK


YEARSN/A


NCT01377480 CHILE MERCK DRUG 2. RECRUITING 2 16018

YEARS50

YEARSCHAGAS DISEASE

NCT01445678 CHILE CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01571284 CHILE SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01663402 CHILE SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01377480 COLOMBIA MERCK DRUG 2. RECRUITING 2 16018

YEARS50

YEARSCHAGAS DISEASE

NCT01480479 COLOMBIA CELLDEX DRUG 2. RECRUITING 3 44018


NCT01712516 COLOMBIA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01782326 COLOMBIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01819129 CROATIANOVO NORDISK


YEARSN/A


NCT01445678 CROATIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01782326 CROATIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01696266 CROATIANOVO NORDISK


YEARSN/A


NCT01261325 CZECH REP UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01480479 CZECH REP CELLDEX DRUG 2. RECRUITING 3 44018


NCT01600092 CZECH REP MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01610414 CZECH REP GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER




(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN

NCT01663402 CZECH REP SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01768572 CZECH REP SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01782326 CZECH REP NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01831765 CZECH REPNOVO NORDISK


YEARSN/A


NCT01696266 CZECH REPNOVO NORDISK


YEARSN/A


NCT01571284 DENMARK SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01600092 DENMARK MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01663402 DENMARK SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 DENMARK NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01492504 DENMARK BMS DRUG 2. RECRUITING NA 99018


NCT01696266 DENMARKNOVO NORDISK


YEARSN/A


NCT01712516 EGYPT NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01782326 EGYPT NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01830985 ESTONIA VERTEX DRUG 2. RECRUITING 2 4018

YEARS65


NCT01853878 ESTONIA GSK BIOLOGICAL 2. RECRUITING 2 22018

YEARSN/A LUNG CANCER

NCT01261325 ESTONIA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01445678 ESTONIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01610414 ESTONIA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 ESTONIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01768572 ESTONIA SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01782326 ESTONIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01715909 FINLANDHOFFMANN-LA ROCHE


YEARSINFLUENZA




(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN

NCT01261325 FINLAND UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01571284 FINLAND SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01600092 FINLAND MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01610414 FINLAND GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 FINLAND SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A



YEARSN/A



YEARSN/A


NCT01782326 FINLAND NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01696266 FINLANDNOVO NORDISK


YEARSN/A


NCT01336634 FRANCE GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01696045 FRANCE BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA

NCT01853878 FRANCE GSK BIOLOGICAL 2. RECRUITING 2 22018


NCT01261325 FRANCE UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 FRANCENOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01610414 FRANCE GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 FRANCE SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01712516 FRANCE NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01764997 FRANCE SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01782326 FRANCE NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT00685750 FRANCE GSK PROCEDURE 2. RECRUITING NA 16018


NCT01492504 FRANCE BMS DRUG 2. RECRUITING NA 99018


NCT01855997 FRANCEHOFFMANN-LA ROCHE


YEARSN/A




YEARSINFLUENZA




(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN



YEARSN/A

PULMONARY FIBROSIS

NCT01261325 GERMANY UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 GERMANYNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01445678 GERMANY CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01544491 GERMANY NOVARTIS DRUG 2. RECRUITING 3 106 N/A18


NCT01571284 GERMANY SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01610414 GERMANY GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 GERMANY SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 GERMANY NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01798706 GERMANY SANOFI DRUG 2. RECRUITING 3 34070

YEARSN/A

TYPE 2 DIABETES



YEARS75

YEARSASTHMA

NCT01410890 GERMANY GENZYME BIOLOGICAL 2. RECRUITING 4 20 8 YEARS18


NCT01838616 GERMANY GRENENTHAL DRUG 2. RECRUITING 4 24018

YEARSN/A

NEUROPATHIC PAIN

NCT00685750 GERMANY GSK PROCEDURE 2. RECRUITING NA 16018


NCT01492504 GERMANY BMS DRUG 2. RECRUITING NA 99018




YEARSN/A


NCT01386528 GREECENOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01480479 GREECE CELLDEX DRUG 2. RECRUITING 3 44018


NCT01782326 GREECE NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01712516 GUATEMALA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01782326 GUATEMALA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01897038 HONG KONGHOFFMANN-LA ROCHE



NCT01261325 HONG KONG UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01610414 HONG KONG GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER




(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01663402 HONG KONG SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01846273 HONG KONG NOVARTIS DRUG 2. RECRUITING 4 32018

YEARSN/A


NCT01261325 HUNGARY UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01445678 HUNGARY CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01480479 HUNGARY CELLDEX DRUG 2. RECRUITING 3 44018


NCT01663402 HUNGARY SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01712516 HUNGARY NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01768572 HUNGARY SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01782326 HUNGARY NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01831765 HUNGARYNOVO NORDISK


YEARSN/A


NCT01868061 HUNGARYHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01902134 HUNGARY MENARINI DRUG 2. RECRUITING 3 60018

YEARS80

YEARSACUTE PAIN

NCT01904149 HUNGARY MENARINI DRUG 2. RECRUITING 3 60018

YEARS75

YEARSACUTE PAIN

NCT01696266 HUNGARYNOVO NORDISK


YEARSN/A


NCT01782326 ICELAND NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01261325 INDIA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01480479 INDIA CELLDEX DRUG 2. RECRUITING 3 44018


NCT01782326 INDIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01410890 INDIA GENZYME BIOLOGICAL 2. RECRUITING 4 20 8 YEARS18


NCT01696266 INDIANOVO NORDISK


YEARSN/A


NCT01571284 IRELAND SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01776424 IRELAND BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A


NCT01492504 IRELAND BMS DRUG 2. RECRUITING NA 99018





(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN

NCT01819129 ISRAELNOVO NORDISK


YEARSN/A


NCT01846611 ISRAEL JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A




YEARSINFLUENZA


YEARSN/A

COLORECTAL CANCER

NCT01600092 ISRAEL MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01610414 ISRAEL GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 ISRAEL SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A



YEARSN/A




YEARS75

YEARSASTHMA

NCT01696266 ISRAELNOVO NORDISK


YEARSN/A




YEARSINFLUENZA

NCT01854047 ITALY SANOFI DRUG 2. RECRUITING 2 60018

YEARSN/A ASTHMA



YEARSN/A

PULMONARY FIBROSIS

NCT01261325 ITALY UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 ITALYNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B


YEARSN/A

COLORECTAL CANCER

NCT01610414 ITALY GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 ITALY SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A



YEARSN/A


NCT01776424 ITALY BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A


NCT01782326 ITALY NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD



YEARS75

YEARSASTHMA




(Return to Page 1)

























miN AGe

mAX AGe CoNdiTioN

NCT00685750 ITALY GSK PROCEDURE 2. RECRUITING NA 16018


NCT01492504 ITALY BMS DRUG 2. RECRUITING NA 99018


NCT01853878 JAPAN GSK BIOLOGICAL 2. RECRUITING 2 22018


NCT01386528 JAPANNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01610414 JAPAN GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01761266 JAPAN EISAI DRUG 2. RECRUITING 3 94018

YEARSN/A

HEPATOCELLU-LAR CARCI-NOMA

NCT01776424 JAPAN BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A


NCT01868061 JAPANHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01846273 JAPAN NOVARTIS DRUG 2. RECRUITING 4 32018

YEARSN/A


NCT01492504 JAPAN BMS DRUG 2. RECRUITING NA 99018


NCT01336634 KOREA, SOUTH GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01853878 KOREA, SOUTH GSK BIOLOGICAL 2. RECRUITING 2 22018


NCT01261325 KOREA, SOUTH UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01445678 KOREA, SOUTH CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01610414 KOREA, SOUTH GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 KOREA, SOUTH SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 KOREA, SOUTH NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD


YEARSN/A


NCT01855997 KOREA, SOUTHHOFFMANN-LA ROCHE


YEARSN/A


NCT01261325 LATVIA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01663402 LATVIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 LATVIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01902134 LATVIA MENARINI DRUG 2. RECRUITING 3 60018

YEARS80

YEARSACUTE PAIN




(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN

NCT01904149 LATVIA MENARINI DRUG 2. RECRUITING 3 60018

YEARS75

YEARSACUTE PAIN

NCT01571284 LEBANON SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01445678 LITHUANIA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01663402 LITHUANIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 LITHUANIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01386528 MACEDONIANOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01610414 MALAYSIA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 MALAYSIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01377480 MEXICO MERCK DRUG 2. RECRUITING 2 16018

YEARS50

YEARSCHAGAS DISEASE

NCT01696045 MEXICO BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA

NCT01261325 MEXICO UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01480479 MEXICO CELLDEX DRUG 2. RECRUITING 3 44018


NCT01663402 MEXICO SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01764997 MEXICO SANOFI DRUG 2. RECRUITING 3 70018

YEARSN/A


NCT01768572 MEXICO SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01492504 MEXICO BMS DRUG 2. RECRUITING NA 99018


NCT01696266 MEXICONOVO NORDISK


YEARSN/A


NCT01445678 MOLDOVA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01336634 NETHERLANDS GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01261325 NETHERLANDS UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 NETHERLANDSNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01571284 NETHERLANDS SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER




(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01663402 NETHERLANDS SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01768572 NETHERLANDS SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01776424 NETHERLANDS BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A


NCT01782326 NETHERLANDS NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01696266 NETHERLANDSNOVO NORDISK


YEARSN/A


NCT01480479 NEW ZEALAND CELLDEX DRUG 2. RECRUITING 3 44018


NCT01610414 NEW ZEALAND GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 NEW ZEALAND SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01868061 NEW ZEALANDHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01855997 NEW ZEALANDHOFFMANN-LA ROCHE


YEARSN/A


NCT01336634 NORWAY GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER


YEARSN/A

COLORECTAL CANCER

NCT01663402 NORWAY SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A



YEARSN/A


NCT01782326 NORWAY NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01610414 PANAMA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01712516 PANAMA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01480479 PERU CELLDEX DRUG 2. RECRUITING 3 44018


NCT01663402 PERU SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01868061 PERUHOFFMANN-LA ROCHE


YEARS75

YEARSASTHMA

NCT01663402 PHILIPPINES SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A




YEARSINFLUENZA


(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01261325 POLAND UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01445678 POLAND CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01480479 POLAND CELLDEX DRUG 2. RECRUITING 3 44018


NCT01600092 POLAND MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01663402 POLAND SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01727141 POLAND NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01768572 POLAND SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01782326 POLAND NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD



YEARS75

YEARSASTHMA

NCT01904149 POLAND MENARINI DRUG 2. RECRUITING 3 60018

YEARS75

YEARSACUTE PAIN

NCT01696266 POLANDNOVO NORDISK


YEARSN/A




YEARSN/A


NCT01663402 PORTUGAL SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 PORTUGAL NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01386528 ROMANIANOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01663402 ROMANIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01727141 ROMANIA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01768572 ROMANIA SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A


NCT01782326 ROMANIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01696266 ROMANIANOVO NORDISK


YEARSN/A


NCT01855997 ROMANIAHOFFMANN-LA ROCHE


YEARSN/A


NCT01853878 RUSSIA GSK BIOLOGICAL 2. RECRUITING 2 22018



(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01261325 RUSSIA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01571284 RUSSIA SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01610414 RUSSIA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 RUSSIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01768572 RUSSIA SANOFI DRUG 2. RECRUITING 3 20018

YEARSN/A




YEARS75

YEARSASTHMA

NCT01819129 SERBIANOVO NORDISK


YEARSN/A


NCT01768702 SERBIA CARDIO3 BIOLOGICAL 2. RECRUITING 3 24018

YEARS80

YEARSHEART FAILURE

NCT01696266 SERBIANOVO NORDISK


YEARSN/A


NCT01897038 SINGAPOREHOFFMANN-LA ROCHE



NCT01663402 SINGAPORE SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01846273 SINGAPORE NOVARTIS DRUG 2. RECRUITING 4 32018

YEARSN/A


NCT01663402 SLOVAKIA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01712516 SLOVAKIA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01782326 SLOVAKIA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01904149 SLOVAKIA MENARINI DRUG 2. RECRUITING 3 60018

YEARS75

YEARSACUTE PAIN

NCT01696266 SLOVAKIANOVO NORDISK


YEARSN/A


NCT01712516 SLOVENIA NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD

NCT01696266 SLOVENIANOVO NORDISK


YEARSN/A


NCT01846611 SOUTH AFRICA JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A




YEARSINFLUENZA

NCT01386528 SOUTH AFRICANOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01610414 SOUTH AFRICA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER


(Return to Page 1)




























miN AGe

mAX AGe CoNdiTioN

NCT01663402 SOUTH AFRICA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A

ACUTECORONARY SYNDROME

NCT01782326 SOUTH AFRICA NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD



YEARS75

YEARSASTHMA

NCT01296555 SPAIN GENENTECH DRUG 2. RECRUITING 1 21918

YEARSN/A

SOLIDCANCERS

NCT01715909 SPAINHOFFMANN-LA ROCHE


YEARSINFLUENZA

NCT01822613 SPAIN NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A


NCT01336634 SPAIN GSK DRUG 2. RECRUITING 2 60 18 YEARS N/A CANCER


YEARSN/A ASTHMA



YEARSN/A

PULMONARY FIBROSIS

NCT01261325 SPAIN UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 SPAINNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B


YEARSN/A

COLORECTAL CANCER

NCT01600092 SPAIN MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01610414 SPAIN GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 SPAIN SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01727141 SPAIN NOVARTIS DRUG 2. RECRUITING 3 1,000 40 YEARS N/A COPD


YEARSN/A


NCT01782326 SPAIN NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD


YEARSN/A

TYPE 2 DIABETES



YEARS75

YEARSASTHMA

NCT01492504 SPAIN BMS DRUG 2. RECRUITING NA 99018


NCT01261325 SWEDEN UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01571284 SWEDEN SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01600092 SWEDEN MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS



(Return to Page 1)



























miN AGe

mAX AGe CoNdiTioN

NCT01663402 SWEDEN SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A



YEARSN/A


NCT01776424 SWEDEN BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A


NCT01782326 SWEDEN NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD


YEARSN/A

TYPE 2 DIABETES

NCT01492504 SWEDEN BMS DRUG 2. RECRUITING NA 99018


NCT01696266 SWEDENNOVO NORDISK


YEARSN/A

DIABETE MEL-LITUS, TYPE 2

NCT01663402 SWITZERLAND SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01711619 SWITZERLAND MEDTRONIC DEVICE 2. RECRUITING 4 20018

YEARSN/A

FAILED BACK SURGERY

NCT01261325 TAIWAN UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY

NCT01386528 TAIWANNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01480479 TAIWAN CELLDEX DRUG 2. RECRUITING 3 44018


NCT01663402 TAIWAN SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01846273 TAIWAN NOVARTIS DRUG 2. RECRUITING 4 32018

YEARSN/A


NCT01480479 THAILAND CELLDEX DRUG 2. RECRUITING 3 44018


NCT01571284 THAILAND SANOFI DRUG 2. RECRUITING 3 90018

YEARSN/A

COLORECTAL CANCER

NCT01782326 THAILAND NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01846273 THAILAND NOVARTIS DRUG 2. RECRUITING 4 32018

YEARSN/A


NCT01386528 TURKEYNOVO NORDISK


YEARS70

YEARSHAEMOPHILIA B

NCT01610414 TURKEY GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01782326 TURKEY NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD

NCT01663402 UKRAINE SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01727141 UKRAINE NOVARTIS DRUG 2. RECRUITING 3 1,00040

YEARSN/A COPD



(See Studies opening Additional Sites in a Country, Page 37)(Return to Page 1)


























miN AGe

mAX AGe CoNdiTioN



YEARSN/A


NCT01846611 UK JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A


NCT01336634 UK GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER

NCT01362244 UK GSK DRUG 2. RECRUITING 2 11018

YEARS70

YEARSPOLYPS, NASAL

NCT01696045 UK BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA

NCT01853878 UK GSK BIOLOGICAL 2. RECRUITING 2 22018


NCT01261325 UK UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY



YEARS70

YEARSHAEMOPHILIA B


YEARSN/A

COLORECTAL CANCER

NCT01610414 UK GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 UK SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01782326 UK NOVARTIS DRUG 2. RECRUITING 3 3,332 N/A N/A COPD


YEARSN/A

TYPE 2 DIABETES

NCT01711619 UK MEDTRONIC DEVICE 2. RECRUITING 4 20018

YEARSN/A

FAILED BACK SURGERY

NCT01492504 UK BMS DRUG 2. RECRUITING NA 99018


NCT01855997 UKHOFFMANN-LA ROCHE


YEARSN/A


NCT01846611 USA JANSSEN DRUG 1. PLANNING 3 67018

YEARSN/A


NCT01296555 USA GENENTECH DRUG 2. RECRUITING 1 21918

YEARSN/A

SOLID CANCERS



YEARSINFLUENZA

NCT01794520 USA ABBVIE DRUG 2. RECRUITING 1 3018

YEARSN/A

MULTIPLE MYELOMA

NCT01822613 USA NOVARTIS DRUG 2. RECRUITING 1 9918

YEARSN/A





NCT01336634 USA GSK DRUG 2. RECRUITING 2 6018

YEARSN/A CANCER





























miN AGe

mAX AGe CoNdiTioN

NCT01436487 USA ATHERSYS BIOLOGICAL 2. RECRUITING 2 14018

YEARS83

YEARSISCHEMIC STROKE

NCT01696045 USA BMS BIOLOGICAL 2. RECRUITING 2 3012

YEARS17

YEARSMELANOMA

NCT01786668 USA PFIZER DRUG 2. RECRUITING 2 20018

YEARSN/A

ANKYLOSING SPONDYLITIS

NCT01830985 USA VERTEX DRUG 2. RECRUITING 2 4018

YEARS65


NCT01854047 USA SANOFI DRUG 2. RECRUITING 2 60018

YEARSN/A ASTHMA



YEARSN/A

PULMONARY FIBROSIS

NCT01261325 USA UCB DRUG 2. RECRUITING 3 72016

YEARS80

YEARSEPILEPSY



YEARS70

YEARSHAEMOPHILIA B

NCT01445678 USA CUBIST DRUG 2. RECRUITING 3 50018

YEARSN/A


NCT01480479 USA CELLDEX DRUG 2. RECRUITING 3 44018


NCT01544491 USA NOVARTIS DRUG 2. RECRUITING 3 106 N/A18



YEARSN/A

COLORECTAL CANCER

NCT01600092 USA MERCK BIOLOGICAL 2. RECRUITING 3 924 6 WEEKS12

WEEKS


NCT01610414 USA GSK BIOLOGICAL 2. RECRUITING 3 1,47418

YEARSN/A

HERPES ZOSTER

NCT01663402 USA SANOFI DRUG 2. RECRUITING 3 18,00040

YEARSN/A


NCT01712516 USA NOVARTIS DRUG 2. RECRUITING 3 1,000 40 YEARS N/A COPD

NCT01727141 USA NOVARTIS DRUG 2. RECRUITING 3 1,000 40 YEARS N/A COPD


YEARSN/A



YEARSN/A


NCT01776424 USA BAYER DRUG 2. RECRUITING 3 19,50018

YEARSN/A



YEARSN/A

TYPE 2 DIABETES



YEARS75

YEARSASTHMA



YEARS17

YEARSASTHMA

NCT01410890 USA GENZYME BIOLOGICAL 2. RECRUITING 4 20 8 YEARS18































miN AGe

mAX AGe CoNdiTioN

NCT00685750 USA GSK PROCEDURE 2. RECRUITING NA 160 18 YEARS N/A LUNG CANCER

NCT01492504 USA BMS DRUG 2. RECRUITING NA 990 18 YEARS N/A HEPATITIS C



(Return to Page 1)

COUNTRY

STUDIES OPENING A

FIRST SITE IN A NEW COUNTRY

STUDIES OPENING ADDITIONAL SITES

IN A COUNTRYTOTAL

TRIALS

ARGENTINA 5 5 10

AUSTRALIA 5 8 13

AUSTRIA 3 7 10

BELGIUM 6 14 20

BRAZIL 4 4 8

BULGARIA 3 7 10

CANADA 10 14 24

CHILE 0 4 4

CHINA 2 0 2

COLOMBIA 3 4 7

CROATIA 0 4 4

CZECH REPUBLIC

5 9 14

DENMARK 3 6 9

EGYPT 0 2 2

ESTONIA 0 8 8

FINLAND 1 10 11

FRANCE 6 13 19

GERMANY 16 17 33

GREECE 1 3 4

GUATEMALA 0 2 2

HONG KONG 2 5 7

HUNGARY 5 12 17

ICELAND 0 1 1

INDIA 2 5 7

IRELAND 0 3 3

ISRAEL 8 10 18

ITALY 3 14 17

JAPAN 6 8 14

KOREA, SOUTH 6 9 15

LATVIA 1 5 6

LEBANON 1 1 2

STudy SiTeS by CouNTryThis table lists all countries with first-time and additional study sites that launched in the past week.

COUNTRY

STUDIES OPENING A

FIRST SITE IN A NEW COUNTRY

STUDIES OPENING ADDITIONAL SITES

IN A COUNTRYTOTAL

TRIALS

LITHUANIA 3 3 6

MACEDONIA 0 1 1

MALAYSIA 2 2 4

MEXICO 4 9 13

MOLDOVA, REPUBLIC OF

0 1 1

NETHERLANDS 4 9 13

NEW ZEALAND 5 5 10

NORWAY 3 5 8

PANAMA 0 2 2

PERU 1 3 4

PHILIPPINES 2 1 3

POLAND 8 13 21

PORTUGAL 0 2 2

ROMANIA 2 7 9

RUSSIA 9 7 16

SERBIA 1 3 4

SINGAPORE 2 3 5

SLOVAKIA 3 5 8

SLOVENIA 0 2 2

SOUTH AFRICA 5 7 12

SPAIN 5 18 23

SWEDEN 3 10 13

SWITZERLAND 0 2 2

TAIWAN 6 5 11

THAILAND 2 4 6

TURKEY 2 3 5

UKRAINE 2 2 4

UNITED KINGDOM

11 16 27

UNITED STATES

31 33 64

VIETNAM 1 0 1




ideNTifier1 SpoNSor Type2 STATuS pHASe3 SiZe (N) miN AGe mAX AGe CoNdiTioN

NCT01691261 PFIZER BIOLOGICAL 1. PLANNING 1 10 61 YEARS N/AMACULAR DEGENERATION

NCT01691807 GSK DRUG 1. PLANNING 1 30 18 YEARS N/A CANCER

NCT01705158 ARCAGY DRUG 1. PLANNING 1 88 18 YEARS N/A OVARIAN CANCER

NCT01728207 IMMUNOMEDICS DRUG 1. PLANNING 1 50 18 YEARS N/ALYMPHOCYTIC LYMPHOMA

NCT01744808 NEUROVANCE DRUG 1. PLANNING 1 58 18 YEARS45

YEARSNORMAL, HEALTHY VOLUNTEERS

NCT01745120 BLUEBIRD GENETIC 1. PLANNING 1 15 18 YEARS35

YEARSBETA-THALASSEMIA MAJOR

NCT01748864 ENDOCYTE DRUG 1. PLANNING 1 10 18 YEARS N/A HEALTHY

NCT01636128CANCER PREVENTION

DRUG 1. PLANNING 2 16 40 YEARS65

YEARSBIOMARKERS

NCT01640847 CELSION DRUG 1. PLANNING 2 52 18 YEARS N/A ADENOCARCINOMA

NCT01750931 GSK DRUG 1. PLANNING 2 28 18 YEARS45

YEARSARTHRITIS, RHEUMATOID

NCT01755598 GSK BIOLOGICAL 1. PLANNING 2 4,500 18 YEARS50

YEARSTUBERCULOSIS VACCINES

NCT01769027 CNS ONLUS DRUG 1. PLANNING 2 30 4 YEARS40

YEARSPANDAS

NCT01622569 OPTINOSE DRUG 1. PLANNING 3 320 18 YEARS N/ABILATERAL NASAL POLYPOSIS

NCT01623310 OPTINOSE DRUG 1. PLANNING 3 200 18 YEARS N/A CHRONIC SINUSITIS

NCT01623323 OPTINOSE DRUG 1. PLANNING 3 700 18 YEARS N/A CHRONIC SINUSITIS

NCT01624662 OPTINOSE DRUG 1. PLANNING 3 320 18 YEARS N/ABILATERAL NASAL POLYPOSIS

NCT01626794 MERCK BIOLOGICAL 1. PLANNING 3 52012

MONTHS23

MONTHSVARICELLA

NCT01652209 PHARMICELL BIOLOGICAL 1. PLANNING 3 135 20 YEARS70

YEARSACUTE INFARCTION

NCT01659801 HANITA DEVICE 1. PLANNING 3 35 40 YEARS80

YEARSCATARACT

NCT01667393 IDEV DEVICE 1. PLANNING 3 318 18 YEARS N/APERIPHERAL VASCULAR DISEASE

NCT01670552 EMS DRUG 1. PLANNING 3 206 18 YEARS65

YEARSDYSPEPSIA

NCT01693120 MEDTRONIC DEVICE 1. PLANNING 3 300 18 YEARS70

YEARSPERSISTENT ATRIAL FIBRILLATION

NCT01694966 COSMO DRUG 1. PLANNING 3 1,270 50 YEARS75

YEARSCOLORECTAL CANCER

NCT01701349 OXIGENE DRUG 1. PLANNING 3 300 18 YEARS N/AANAPLASTIC THYROID CANCER

STudieS uNder plANNiNG

This table lists all registered studies that are still under planning, have no site location listed and was first registered during the past year. About 10% of the studies listed as in the planning stage are replaced each week.


(See Studies under planning, Page 41)(Return to Page 1)


























ideNTifier1 SpoNSor Type2 STATuS pHASe3 SiZe (N) miN AGe mAX AGe CoNdiTioN

NCT01709084 JANSSEN DRUG 1. PLANNING 3 426 18 YEARS N/A HIV

NCT01751126 NOVAGALI DRUG 1. PLANNING 3 168 4 YEARS18

YEARSVERNAL KERATO-CONJUNCTIVITIS

NCT01753180 MATRIZYME BIOLOGICAL 1. PLANNING 3MISS-ING

18 YEARS80

YEARSCHRONIC TOTAL OCCLUSIONS

NCT01613677 NOVARTIS DRUG 1. PLANNING 4 27 18 YEARS N/A CERVICAL CANCER

NCT01692470 JANSSEN DRUG 1. PLANNING 4 60 18 YEARS N/A HIV

NCT01727271 MERCK DRUG 1. PLANNING 4 150 18 YEARS N/A HEPATITIS B

NCT01758198 BMS BIOLOGICAL 1. PLANNING 4 300 20 YEARS N/ARHEUMATOID ARTHRITIS

NCT01629719 ALKO 1. PLANNING NA 73 18 YEARS N/A X-RAY GI

NCT01638286 HANMI 1. PLANNING NA 24 20 YEARS45

YEARSACUTE LOW BACK PAIN

NCT01645371 ASTRAZENECA 1. PLANNING NA 70 18 YEARS84

YEARSOPIOID-INDUCED CONSTIPATION

NCT01674764 AOSPINE PROCEDURE 1. PLANNING NA 300 18 YEARS N/AACUTE SPINAL CORD INJURY

NCT01683305 SILBIOTECH 1. PLANNING NA 500 18 YEARS N/A TUMORS

NCT01685047 ST JUDE 1. PLANNING NA 470 18 YEARS N/ACORONARY ARTERY DISEASE

NCT01688011 CELGENE 1. PLANNING NA 1,500 18 YEARS N/AACUTE MYELOID LEUKEMIA

NCT01700543 ZIMMER PROCEDURE 1. PLANNING NA 160 18 YEARS80


NCT01719263 UPTAKE DEVICE 1. PLANNING NA 69 40 YEARS 75 YEARS EMPHYSEMA

NCT01728103 GEN-PROBE DEVICE 1. PLANNING NA 2,100 16 YEARS N/ATRICHOMONAS INFECTIONS

NCT01728714 ASTRAZENECA 1. PLANNING NA 250 18 YEARS N/A DIABETES TYPE 2

NCT01733368 ST JUDE 1. PLANNING NA 200 18 YEARS N/A HEART FAILURE

NCT01735188 ALEXION OTHER 1. PLANNING NA 30 N/A N/ASULFITE OXIDASE DEFICIENCIES

NCT01741025 SI-BONE DEVICE 1. PLANNING NA 100 21 YEARS70

YEARSSACROILIAC JOINT PAIN

NCT01751139 GSK PROCEDURE 1. PLANNING NA 1,500 6 MONTHS N/A DENGUE VACCINES

Studies under planning, from Page 40


(See Studies ended or Halted, Page 42)(Return to Page 1)


miN AGe

mAX AGe CoNdiTioN

NCT01793649 GILEAD DRUG 5. SUSPENDED 1 12 18 YEARS 45 YEARS COPD

NCT01870297 ELI LILLY DRUG 5. SUSPENDED 1 74 21 YEARS 70 YEARSTYPE 2 DIABETES MELLITUS

NCT01546350REPROGE-NETICS

GENETIC 5. SUSPENDED 2 200 32 YEARS 42 YEARS PREGNANCY LOSS

STudieS eNded or HAlTed

This table lists studies that were terminated, suspended or withdrawn in the past week.




























Clinical Trial Magnifier Limited: Managing Director, Johan PE Karlberg fdAnews: president, Cynthia Carter; Content director: Dan Landrigan; executive editor: Meg BryantCopyright © 2013 by Clinical Trial Magnifier. All rights reserved. Clinical Trial Magnifier Weekly is produced jointly by Clinical Trial Magni-fier Limited, which is responsible for the content, and FDAnews, which is responsible for production and distribution. Clinical Trial Magni-fier Weekly (ISSN 2306-8388) monitors all the essential changes made in the U.S. trial registry for industry-sponsored clinical studies. It is published weekly, 52 issues. Price for nonprofit, academic, government, hospital, and study site subscribers, $697. Price for for-profit, in-dustry, and clinical research organizations, $1,297. For site license pricing, contact Nelly Valentin, [email protected]. Photocopying or reproducing in any form, including electronic or facsimile transmission, scanning or electronic storage is a violation of federal copyright law and is strictly prohibited without the publisher’s express written permission.

300 N. Washington St., Suite 200 • Falls Church, VA 22046-3431 • Phone: (888) 838-5578 • +1 (703) 538-7600 • Fax: +1 (703) 538-7676www.fdanews.com

Customer Service: Kim Williams editorial: Dan Landrigan Ad Sales: Jim Desborough Content Sales: Nelly Valentin(888) 838-5578 • +1 (703) 538-7600 (703) 538-7649 (703) 538-7647 (703) [email protected] [email protected] [email protected] [email protected]


miN AGe

mAX AGe CoNdiTioN

NCT01694485 AMGEN BIOLOGICAL 5. SUSPENDED 2 360 18 YEARS 65 YEARS ULCERATIVE COLITIS


BIOLOGICAL 7. TERMINATED 1 9 16 YEARS N/A KIDNEY CANCER

NCT01114503 GSK DRUG 7. TERMINATED 1 30 18 YEARS 75 YEARSGRAVES OPHTHALMOPATHY

NCT00413192 EISAI DRUG 7. TERMINATED 2 128 18 YEARS N/ASOFT TISSUE SARCOMA

NCT00505570 AGA DEVICE 7. TERMINATED 2 10718

YEARS65

YEARSPFO


BIOLOGICAL 7. TERMINATED 2 80 18 YEARS N/A BRAIN TUMORS

NCT01602367 BMS DRUG 7. TERMINATED 2 718

YEARS80

YEARSHYPERTENSION

NCT01705496 BIOMED RADIATION 7. TERMINATED 2 24 18 YEARS N/APROSTHETIC INFECTIONS

NCT01764919 BIOMED RADIATION 7. TERMINATED 2 4 18 YEARS N/ADIABETIC FOOT INFECTION

NCT01308437WOCK-HARDT

BIOLOGICAL 7. TERMINATED 3 134 18 YEARS 55 YEARS TYPE I DIABETES

NCT00292500 CARDICA DEVICE 7. TERMINATED NA 170 50 YEARS 85 YEARSCORONARY ARTERY DISEASE

NCT01197209MOMOTARO-GENE

BIOLOGICAL 8. WITHDRAWN 1 0 20 YEARS 75 YEARS PROSTATE CANCER

NCT01697514 ELI LILLY DRUG 8. WITHDRAWN 1 012

MONTHS21 YEARS

RHABDOMYOSAR-COMA

NCT01721135 GSK DRUG 8. WITHDRAWN 1 0 18 YEARS 65 YEARS ASTHMA

NCT01404117 TEVA DRUG 8. WITHDRAWN 2 0 18 YEARS 55 YEARSMULTIPLE SCLEROSIS

NCT01723579 MERCK DRUG 8. WITHDRAWN 3 0 18 YEARS 45 YEARS CONTRACEPTION

NCT01757015 NOVARTIS DRUG 8. WITHDRAWN 3 0 40 YEARS N/A COPD

NCT01380665 KCI DEVICE 8. WITHDRAWN 4 0 18 YEARS N/AKNEE ARTHROPLASTY

NCT00234559 KCI DEVICE 8. WITHDRAWN NA 0 18 YEARS N/A WOUNDS

NCT01701947 FRANCAIS BIOLOGICAL 8. WITHDRAWN NA MISS-ING

6 MONTHS N/A SURGERY

Studies ended or Halted, from Page 41

mailto:[email protected]

http://www.fdanews.com

http://www.fdanews.com

























Documents

INsIde thIs Issue - FDAnews · For more details, see New Studies on Page 2. New Results: ... NCT01928056 TORRENT DRUG 4. COMPLETED 1 MISS-ING 18 YEARS 45 YEARS HEALTHY NCT01928069